PT3837256T - Compostos e composições de ureia como inibidores de smarca2/brm-atpase - Google Patents

Compostos e composições de ureia como inibidores de smarca2/brm-atpase

Info

Publication number
PT3837256T
PT3837256T PT197791452T PT19779145T PT3837256T PT 3837256 T PT3837256 T PT 3837256T PT 197791452 T PT197791452 T PT 197791452T PT 19779145 T PT19779145 T PT 19779145T PT 3837256 T PT3837256 T PT 3837256T
Authority
PT
Portugal
Prior art keywords
smarca2
compositions
urea compounds
atpase inhibitors
brm atpase
Prior art date
Application number
PT197791452T
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3837256T publication Critical patent/PT3837256T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
PT197791452T 2018-08-17 2019-08-12 Compostos e composições de ureia como inibidores de smarca2/brm-atpase PT3837256T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862765138P 2018-08-17 2018-08-17

Publications (1)

Publication Number Publication Date
PT3837256T true PT3837256T (pt) 2023-05-23

Family

ID=68072895

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197791452T PT3837256T (pt) 2018-08-17 2019-08-12 Compostos e composições de ureia como inibidores de smarca2/brm-atpase

Country Status (20)

Country Link
EP (2) EP4219488A1 (pt)
JP (1) JP7328323B2 (pt)
KR (1) KR20210047313A (pt)
CN (1) CN112585136A (pt)
AU (1) AU2019322325B2 (pt)
BR (1) BR112021002632A2 (pt)
CA (1) CA3107097A1 (pt)
CY (1) CY1126039T1 (pt)
DK (1) DK3837256T3 (pt)
ES (1) ES2946060T3 (pt)
FI (1) FI3837256T3 (pt)
HR (1) HRP20230477T1 (pt)
HU (1) HUE061963T2 (pt)
LT (1) LT3837256T (pt)
MX (1) MX2021001804A (pt)
PL (1) PL3837256T3 (pt)
PT (1) PT3837256T (pt)
RS (1) RS64238B1 (pt)
SI (1) SI3837256T1 (pt)
WO (1) WO2020035779A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
KR20220133258A (ko) 2020-01-29 2022-10-04 포그혼 쎄라퓨틱스 인크. 화합물 및 이의 용도
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
PL221491B1 (pl) 2002-03-08 2016-04-29 Eisai R&D Man Co Związki makrocykliczne, środek farmaceutyczny zawierający te związki oraz zastosowanie tych związków
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
KR101584823B1 (ko) 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations

Also Published As

Publication number Publication date
EP3837256B1 (en) 2023-03-08
MX2021001804A (es) 2021-04-19
AU2019322325A1 (en) 2021-02-18
DK3837256T3 (da) 2023-05-30
HUE061963T2 (hu) 2023-09-28
CA3107097A1 (en) 2020-02-20
KR20210047313A (ko) 2021-04-29
HRP20230477T1 (hr) 2023-07-21
BR112021002632A2 (pt) 2021-05-11
SI3837256T1 (sl) 2023-07-31
WO2020035779A1 (en) 2020-02-20
JP2021534147A (ja) 2021-12-09
JP7328323B2 (ja) 2023-08-16
FI3837256T3 (fi) 2023-05-15
CY1126039T1 (el) 2023-11-15
AU2019322325B2 (en) 2022-01-20
CN112585136A (zh) 2021-03-30
RS64238B1 (sr) 2023-06-30
EP3837256A1 (en) 2021-06-23
PL3837256T3 (pl) 2023-07-10
EP4219488A1 (en) 2023-08-02
LT3837256T (lt) 2023-06-12
US20210323956A1 (en) 2021-10-21
ES2946060T3 (es) 2023-07-12

Similar Documents

Publication Publication Date Title
IL277079A (en) Cartirin preparations and methods of use
IL282191A (en) Methods and preparations for editing RN" A
IL263082B (en) New compounds as ototaxin inhibitors and pharmaceutical preparations containing them
SG11202104687SA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
HK1249104A1 (zh) 作為HDAC8抑制劑的α-肉桂酰胺化合物和組合物
GB201910135D0 (en) Heterocyclic urea compound and pharmaceutical composition and application thereof
IL268684A (en) Preparations and methods for immuno-oncology
SG11202104686QA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
IL271256A (en) Preparations and methods for the treatment of teopathy
ZA202001320B (en) Compounds and compositions for ire1 inhibition
PT3837256T (pt) Compostos e composições de ureia como inibidores de smarca2/brm-atpase
PH12018500504A1 (en) Compounds useful for inhibiting ror-gamma-t
IL258411B (en) Hydroxyalkyl thiadiazole derivatives, preparations containing them and their uses
IL274524A (en) Preparations and methods for aquaculture
IL280330A (en) Preparations and methods related to agriculture
IL286587A (en) Preparations of d-methyrosine and methods for their preparation
EP3687628A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING ACSS2
EP3638277A4 (en) COMPOSITIONS AND PROCEDURES FOR INHIBITING BETA SECRETASE
EP3568203C0 (en) COMPOUNDS AND COMPOSITIONS
ZA202104192B (en) Mmpl3 inhibitors, compositions and uses thereof
IL287316A (en) compounds and preparations
IL282824A (en) Preparations and methods for treating transient biofilms
GB201806460D0 (en) Pharmaceutical compositions and associated kits
EP3845528C0 (en) PYRAZOLE COMPOUNDS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS IRAK4 INHIBITORS
GB201808668D0 (en) Compounds and compositions and uses thereof